396 related articles for article (PubMed ID: 16735842)
1. Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review.
Boonen S
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S21-7. PubMed ID: 16735842
[TBL] [Abstract][Full Text] [Related]
2. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
3. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages.
Ortolani S; Vai S
Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate.
Cortet B
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv14-9. PubMed ID: 19783589
[TBL] [Abstract][Full Text] [Related]
5. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
6. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
Adami S
Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247
[TBL] [Abstract][Full Text] [Related]
7. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
8. Continuous broad protection against osteoporotic fractures with strontium ranelate.
Ferrari S
Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.
Reginster JY; Bruyère O; Sawicki A; Roces-Varela A; Fardellone P; Roberts A; Devogelaer JP
Bone; 2009 Dec; 45(6):1059-64. PubMed ID: 19679207
[TBL] [Abstract][Full Text] [Related]
10. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age.
Seeman E; Boonen S; Borgström F; Vellas B; Aquino JP; Semler J; Benhamou CL; Kaufman JM; Reginster JY
Bone; 2010 Apr; 46(4):1038-42. PubMed ID: 20026265
[TBL] [Abstract][Full Text] [Related]
11. A new treatment for post-menopausal osteoporosis: strontium ranelate.
Rizzoli R
J Endocrinol Invest; 2005; 28(8 Suppl):50-7. PubMed ID: 16323829
[TBL] [Abstract][Full Text] [Related]
12. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis.
Neuprez A; Hiligsmann M; Scholtissen S; Bruyere O; Reginster JY
Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755
[TBL] [Abstract][Full Text] [Related]
13. Effects of strontium ranelate on spinal osteoarthritis progression.
Bruyere O; Delferriere D; Roux C; Wark JD; Spector T; Devogelaer JP; Brixen K; Adami S; Fechtenbaum J; Kolta S; Reginster JY
Ann Rheum Dis; 2008 Mar; 67(3):335-9. PubMed ID: 17965119
[TBL] [Abstract][Full Text] [Related]
14. Strontium as therapy for osteoporosis.
Marie PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330
[TBL] [Abstract][Full Text] [Related]
15. Strontium ranelate in the prevention of osteoporotic fractures.
Reginster JY; Malaise O; Neuprez A; Bruyere O
Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
17. [Strontium Ranelate as a new therapeutic agent for osteoporosis].
Imanishi Y; Nishizawa Y
Clin Calcium; 2005 Jan; 15(1):25-8. PubMed ID: 15632469
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.
Delmas PD
Osteoporos Int; 2005 Jan; 16 Suppl 1():S16-9. PubMed ID: 15578158
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Hiligsmann M; Bruyère O; Reginster JY
Bone; 2010 Feb; 46(2):440-6. PubMed ID: 19716940
[TBL] [Abstract][Full Text] [Related]
20. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
